(24/7 MARKET NEWS) – Telesis Bio Inc. (NASDAQ: TBIO), reported, after yesterday’s market close, financial results for the fourth quarter and year ended December 31, 2022 financial results and provided financial guidance for 2023. Results included record revenue of $9.5 million in the fourth quarter, an increase of 208% over the 2021 fourth quarter.
Telesis Bio is trading at $2.71, up $0.50 (+22.46%), on 900 thousand shares traded.
Its 52-week trading range is $1.0801 to $8.75. If its trading volume picks up it has a potential pathway to the mid $3 level or higher.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
